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Abstract 
The development of acute myeloid leukaemia after low-dose radioiodine therapy and its 
presentation as a myeloid sarcoma of the uterine cervix are both rare events. We report a 
case of acute myeloid leukaemia revealed by a myeloid sarcoma of the uterine cervix in a 
48-year-old woman, 17 months after receiving a total dose of 100 mCi 131I for papillary 
thyroid cancer. A strict hematological follow-up of patients treated with any dose of 131I 
is recommended to accurately detect any hematological complications which might 
have been underestimated. Unusual presentations, such as chloroma of the uterine 
cervix, may reveal myeloid malignancy and should be kept in mind. 
 
Introduction 
Myeloid sarcoma (MS) are solid tumours composed of immature myeloid cells 
involving an extramedullary site [1]. These tumours are also named chloroma in view of 
their green coloration due to high myeloperoxydase content [1]. MS occurs mainly in 
patients with known acute myeloid leukaemia (AML), myeloproliferative disorder or 
myelodysplastic syndrome [1, 2]. In few cases, MS may be the presenting feature of AML,  
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and the most common sites of involvement are bones, soft tissue, lymph nodes, skin, 
gastrointestinal tract and body cavities [2]. Presentations in the female genital tract (FGT) 
are uncommon [2]. 
Radioiodine (
131I) is used in the treatment of thyroid cancer in order to eliminate 
residual thyroid tissue following total thyroidectomy and to treat metastatic disease [3, 4]. 
It is known that ionizing radiations, including 
131I, are highly effective in producing 
chromosomal aberrations that sometimes are linked to the occurrence of secondary 
leukaemia [5]. AML is an uncommon complication of exposure to 
131I, occurring mostly 
after a cumulative dose higher than 800 mCi [3, 5]. Although cases of patients developing 
leukaemia after low-dose radioactive iodine are reported [3–10], the link with the 
treatment is still a matter of debate. We report a case of acute myeloid leukaemia revealed 
by a MS of the uterine cervix in a 48-year-old woman, 17 months after receiving a total 
dose of 100 mCi 
131I for papillary thyroid cancer. We also present a review of the 
literature. 
Case Presentation 
A 48-year-old woman, gravida 3, para 3, was referred to our unit in April 2007 for a large uterine 
cervical mass detected during an intrauterine device change. Her medical history was marked by a total 
thyroidectomy for papillary carcinoma performed 17 months before. Surgical intervention was followed 
by radioiodine therapy. She received a single dose of 100 mCi radioiodine (
131I) and a suppressive dose 
of thyroid hormone. Six months later she had a negative whole-body 
131I scan. 
On admission, besides pallor and moderate asthenia, the physical examination revealed a large gray-
green-tinged cervical mass extended to both parametriae. Her last gynecological examination and PAP 
smear (one year before) were normal, as were the last laboratory examinations. Cervical smear 
performed by the gynecologist revealed the presence of atypical squamous cells of undetermined 
significance (ASCUS-Bethesda System 2001). Imaging confirmed the presence of a homogeneous 
cervical tumour measuring 6 cm, extending to both parametriae. Large periaortic and iliac lymph nodes 
were detected. Cervical biopsy showed cervical stroma being infiltrated by sheets of medium sized 
immature cells, many of which had clear cytoplasm (fig. 1; hematoxylin and eosin stain; original 
magnification × 200). Immunohistochemical analysis showed that the neoplastic cells were strongly 
positive for myeloperoxydase (fig. 2; original magnification × 200), CD 117 and CD 34 antigens, leading 
to the diagnosis of MS. Laboratory examinations revealed the following values: hemoglobin 5.4 g/dl, 
hematocrit 16%, white blood cell count 5.1 × 10
3/mm
3 with 75% of blast cells and a platelet count of 19 
× 10
3/mm
3. A bone marrow biopsy confirmed the diagnosis of acute AML type M2 according to the 
French-American-British Classification Scheme. Cytogenetic studies on bone marrow cells failed to 
show any translocation or inversion, but demonstrated a trisomy 3 confirmed by FISH. 
Induction treatment was carried out using high-dose cytarabine and daunorubicin according to 
LAM 2006 protocol. As the medullogram showed 66% pathological blasts 15 days after the beginning of 
the treatment, the patient underwent reinduction therapy using the same drugs. The patient’s course 
was complicated by febrile neutropenia and staphylococcal sepsis which was successfully treated. A 
post-chemotherapy medullogram done prior to discharge in May 2007 showed a hypocellular marrow 
with 3% blasts (1% pathological blasts). Biopsies of the female genital tract showed no leukaemic blasts. 
One month later, a bone marrow biopsy showed the persistence of 11% pathological blasts. A 
compensation treatment according to the LAM 2006 protocol (high doses of amsacrine and aracytine) 
was performed. The patient achieved complete remission. Consolidation courses are being 
administered. 
Discussion 
MS are solid tumours composed of immature myeloid cells involving an 
extramedullary site [1]. They occur mainly in patients with known AML, 
myeloproliferative disorder or myelodysplastic syndrome. In very few cases, MS may be  
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the presenting feature of AML [1, 2]. MS of the uterine cervix as an initial clinical 
presentation of acute myeloid leukaemia is uncommon [1, 2]. Radioiodine is used in the 
treatment of thyroid cancer in order to eliminate residual thyroid tissue following total 
thyroidectomy and to treat metastatic disease [3, 4]. AML is an uncommon complication 
of exposure to 
131I, which when it occurs, does so mostly after cumulative doses higher 
than 800 mCi [3, 5]. Although cases of patients developing leukaemia after low-dose 
radioactive iodine are reported [3–10], the link with the treatment is still a matter of 
debate. In this report, a routine gynecological examination led to the diagnosis of 
chloroma which revealed AML. The patient had received a single dose of 100 mCi 
131I for 
the treatment of a thyroid cancer 17 months before the diagnosis. 
MS occurs most commonly in bone, periosteum, soft tissue, lymph nodes and skin, 
whereas the FGT is rarely involved [1, 2]. The ovaries and breasts deserve special mention 
as sites of involvement [1], but Garcia et al. [2] suggest that the uterine cervix and ovary 
are involved with equal frequency. Only 23 cases of MS of the uterine cervix have been 
reported before [2]. The majority of patients with MS of the cervix present vaginal or 
postcoital bleeding. Other presenting features are abdominal pain or discomfort or a 
combination of these symptoms [2]. MS of the FGT are usually large and green coloured 
[2]. Diagnosis is especially difficult when the tumour mass is isolated with no evidence of 
systemic AML. In these cases, MS are frequently misdiagnosed in biopsies and the most 
common incorrect diagnosis cited is large cell lymphoma. Cytochemical and 
immunohistochemical studies are extremely helpful for establishing the correct diagnosis 
in such cases. Prognosis of MS of the uterine cervix is poor, ranging from an average 
survival of 9 months in patients without manifest leukaemia to 3.2 months for patients 
with manifest AML at presentation [1]. In our case the patient had no history of 
hematologic disorder. She was asymptomatic and an examination of peripheral blood and 
bone marrow after the diagnosis of FGT involvement revealed AML M2. She is still alive 6 
months after the diagnosis. 
The development of AML is a rare but known complication of radioiodine therapy 
usually occurring after a cumulative dose of more than 800 mCi. However, a few cases of 
AML after a lower dose of 
131I have already been reported. Table 1 summarizes a review of 
published reports of acute myeloid leukaemia in patients treated with 
131I for thyroid 
disorders [3–10]. 
Most cases of AML described were in patients younger than 50 years of age. Total 
doses of 
131I were included between 23 and 300 mCi. Two groups can clearly be 
distinguished: patients who developed leukaemia 12 to 24 months after the radioiodine 
therapy, and those whose disease occurred after a period longer than 2 years. Cytogenetic 
analysis of bone marrow showed described chromosomal rearrangement in cases 6 and 7 
(trisomy 8 and t(15,17), respectively) [6]. In our patient a trisomy 3 was highlighted. We 
do not know whether these cases of AML can be considered as a second neoplasia or as a 
secondary effect of radioactive treatment. Nevertheless, ionizing radiation, including 
131I, 
is known to be highly involved in producing chromosome aberrations that could be 
linked to the occurrence of secondary leukaemia [8, 9]. It has actually been shown that the 
frequency of complex abnormalities in karyotypes is higher in radioiodine treatment-
related AML than in de novo AML [6]. 
It is unclear whether treatment with low-dose radioactive iodine contributed to the 
development of leukaemia in the patients described. The development of AML after low-
dose radioiodine could represent a therapy-induced complication. Alternatively, we could 
also hypothesize that the bone marrow of these patients shows individual susceptibilities 
that put them at greater risk for the potential damaging effect of 
131I therapy. Finally, these  
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patients could represent a part of the population that would have developed AML without 
any 
131I therapy. 
As the incidence of leukaemia after low-dose radioiodine therapy is unclear, a strict 
hematological follow-up of patients treated with any dose of 
131I therapy is recommended 
to accurately detect any hematological complication which might have been 
underestimated. Unusual presentations, such as chloroma of the uterine cervix, may 
reveal myeloid malignancy and should therefore be kept in mind. 
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Table 1. Incidence of acute myeloid leukaemia after low-dose radioiodine treatment for thyroid 
disorders 
Case Age 
years 
Dose 
of 
131I 
(mCi) 
Time in 
months from 
131I to AML 
onset 
Type of myeloid 
leukaemia 
Karyo- 
type 
Reference 
01 NA  .100  012   Acute granulocytic  NA  Beierwaltes, 1981 
02 19  .230  024  Acute myeloblastic  NA  Siemsen, 1970 
03 28  .300  014   AML M4  NA  Bitton, 1993 
04 34  .150  024   AML M2  NA  Roldan Schilling, 1998 
05 43  .150  060  AML M3  NA  Roldan Schilling, 1998 
06 48  .023  014  AML M2  Trisomy 8  Laurenti, 1998 
07 47  .118  014  AML M3  t(15,17)  Grudeva-Popova, 2007 
08 55  .090  144  AML M4  Iso 7q  Focosi, 2007 
09 51  22.1  027 AML  M3  NA  Kolade,  2005 
10 48  .100  017  AML M2  Trisomy 3  Our case, 2007 
mCi = Millicurie; Iso = isochromosome; NA = not available. 
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Fig. 1. Hematoxylin and eosin stain of the cervical biopsy showed cervical stroma being infiltrated by 
sheets of medium sized immature cells, many of which had clear cytoplasm (original magnification × 
200). 
 
 
 
Fig. 2. Immunohistochemical analysis showed that the neoplastic cells were strongly positive for 
myeloperoxydase, CD 117 and CD 34 antigens (original magnification × 200). 
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